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SAMPLE AND METHODS 
Newborn Screening: 
Blood spot samples from Portuguese newborns are collected between day 3 and 6 in Whatman 903 
filter paper. Two triple quadrupole tandem mass spectrometers (AbSciex) are used in our laboratory 
to perform the routine MS-MS neonatal screening method, which includes the analysis of 
aminoacids and acylcarnitines as butyl esters (4). Present data results from the screening of 
1,249,175 newborns. 
Diagnosis confirmation: 
All diagnosis were confirmed using organic acid analysis and molecular approaches.. 
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INTRODUCTION 
Expanded Newborn Screening (NBS) programs based on MS/MS, result in a massive 
increase of screened metabolic disorders and detected patients. Alongside with the 
detection of classical forms of screened metabolic disorders, milder forms (many 
whose existence was unknown until now) are being detected, representing major 
challenges in respect to follow up protocols. 
Disease spectrum of screened disorders is being stretched, through the detection of 
undiagnosed mothers through their son’s newborn screening results. In these cases, 
abnormal screening results are due to maternal rather to neonatal disease. The most 
common examples are newborns from mothers 3-mthylcroyonyl-CoA-carboxylase 
deficiency (with newborns usually presenting elevated 3-hydroxy-isovalerylcarnitine 
and/or low free carnitine) and from mothers with Primary Carnitine Deficiency (with 
newborns usually presenting low free carnitine). More rarely low free carnitne values 
in the newborns have been associated to other maternal conditions, namely glutaric 
aciduria type I (1). 
Glutaric aciduria type I (GAI) (MIM# 231670) is an autosomal recessive inherited 
metabolic caused by a defect of the enzyme glutaryl-CoA dehydrogenase. Clinically 
GAI, a neurometabolic disorder firstly described by Goodman (2) is characterised by a 
progressive neurodegeneration that typically manifests acutely in infants during a 
intercorrent illness. The well known phenotypic presentations are fronto-temporal 
brain atrophy with macrocephaly and acute encephalopathic episodes with striatal 
necrosis followed by dystonic-dyskinetic movement disorder (3). 
The authors will present NSB data of newborns from GA I mothers and from the 
mothers themselves. 
RESULTS 
Since 2004, a total of 1.249.175 Portuguese newborns were screened by MS/MS and 
five newborns with acylcarnitine profile abnormalities, due to maternal GA I, were 
detected (1:249.835) (table 1) (figure 1). All newborns present extremely low levels of 
free carnitine (3.36 µM +/- 0.65; normal >9.13) and only one presented a slight 
elevation of glutarylcarnitine (0.22 µM; normal <0.20). During this same period a total 
of 16 newborns with true GA I were detected (1:78.730). 
DISCUSSION 
These maternal cases represent milder forms of the disease, but where follow up is recommended. In order to maximize the detection of maternal conditions is advisable to test 
newborns mothers in all situations of unexpected findings or in situations of very low free carnitine. 
The detection of affected mothers represents an important benefit of expanded newborn screening, with not only direct contributions to patients health but also creating the basis 
for an increasing knowledge on these disorders through the understand of their clinical spectrum. 
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Case Age at sample collection Free carnitine (C0) 
Glutarylcarnitine 
(C5DC) 
1 1 day 3,4 µM (Normal>9,13) 0,22 µM (Normal<0,20) 
Mother of 1 adult Not available Not available 
2 5 days 2,9 µM (Normal>9,13) 0,03 µM (Normal<0,20) 
Mother of 2 adult 2,3 µM (Normal>16,4) 0,33 µM (Normal<0,09) 
3 12 days 3,0 µM (Normal>9,13) 0,03 µM (Normal<0,20) 
Mother of 3 adult 2,3 µM (Normal>16,4) 0,39 µM (Normal<0,09) 
4 4 days 4,5 µM (Normal>9,13) 0,06 µM (Normal<0,20) 
Mother of 4 adult 3,8 µM (Normal>16,4) 0,49 µM (Normal<0,09) 
5 4 days 3,1 µM (Normal>9,13) 0,08 µM (Normal<0,20) 
Mother of 5 adult 2,1 µM (Normal>16,4) 0,68 µM (Normal<0,09) 
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Figure 1: Example of an acylcarnitine profile of a newborn from a Glutaric aciduria 
type I mother and  an acylcarnitine profile from his mother. C0 – free carnitine; C5DC 
– glutarylcarnitine. 
Table1: Free carnitine and glutacrylcarnitine values of the five newborns detected as 
well as of theirs glutaric aciduria type I mothers. 
Results from the mothers of case 1 are not available, since the mother was already 
diagnosed with glutaric aciduria type I, but abandon treatment during all the course of 
the pregnancy. 
